Israeli Microbiome Therapeutics Company BiomX Raises $32M

BiomX Ltd., an Israeli microbiome therapeutics company, announced on Wednesday the closing of a $32 million series B equity financing round led by existing investors OrbiMed, Johnson & Johnson Innovation – JJDC, Inc., Takeda Ventures, Inc., 8VC, MiraeAsset, Seventure Partners’ Health for Life Capital I, and SBI Japan-Israel Innovation Fund. New investors included RM Global Partners (RMGP) BioPharma Investment Fund, Chong Kun Dang Pharmaceutical Corp., Handok, Inc., KB Investment Co., Ltd. and Consensus Business Group.

BiomX develops customized phage therapies that target harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and cancer. The company says it discovers and validates proprietary bacterial targets and customizes its natural and engineered phage compositions against these targets.

Jonathan Solomon, CEO of BiomX, said: “The new funding will enable us to transition BiomX to a clinical stage company as our lead programs in acne and IBD, both novel phage therapeutics targeting harmful bacteria in the microbiome, enter the clinic.”

“The acne program is expected to begin clinical trials by year-end, followed by our IBD program next year. In addition, we will continue to drive our liver disease and colorectal cancer programs forward by identifying key bacteria driving these diseases and developing unique phage cocktails against them,” he added.

BiomX previously raised $24 million in 2017.